References
Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124 DOI 10.1056/NEJMoa065044
Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860–1869 DOI 10.1245/s10434-006-9337-9
Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24:3535
Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186 DOI 10.1200/JCO.2007.12.0782
Gray J, Murren J, Sharma A et al (2007) Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 2:571–573 DOI 10.1097/JTO.0b013e31805fea51
Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35 DOI 10.1200/JCO.2005.02.2194
Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338
Gore M, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:5010
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342 DOI 10.1056/NEJMoa032691
Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019 DOI 10.1200/JCO.2007.14.9930
Garcia AA, Hirte H, Fleming F et al (2008) Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortium. J Clin Oncol 26:76–82 DOI 10.1200/JCO.2007.12.1939
Berger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 25:5165–5177 DOI 10.1200/JCO.2007.11.5345
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676 DOI 10.1056/NEJMoa072113
Sandler A, Gray R, Perry MC (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542–2550 DOI 10.1056/NEJMoa061884
Heng Y, Schuffler MD, Haggitt RC et al (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758
Asmis TR, Chung KY, Teitcher JB et al (2007) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96 DOI 10.1007/s10637-007-9094-z
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flaig, T.W., Kim, F.J., La Rosa, F.G. et al. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 27, 83–87 (2009). https://doi.org/10.1007/s10637-008-9146-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-008-9146-z